Cite
HARVARD Citation
Schumann, F. et al. (2019). Treatment With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (Pcsk9-I) In Clinical Routine – New Data Regarding Familial Hypercholesterolaemia (Fh) Genotype Safety And Efficacy. Atherosclerosis. pp. e215-e216. [Online].